BioSpace News Archive

MDxHealth SA, announced its business update and financial results for the year ended December 31, 2018 and provided its strategic outlook for 2019.

As if expecting mothers didn’t have enough to worry about, a new study published in Risk Analysis: An International Journal found that the quantity of delivery complications in hospitals are substantially higher during nights, weekends and holidays, and in teaching hospitals.

Government-contracting veteran, Keith Smith, will lead IHRC’s operations as the company continues its expansion in both public and private sectors

The educational activity will take place as a satellite symposium adjunct to the Society of Gynecologic Oncology’s (SGO) 50th Annual Meeting on Women’s Cancer

Genentech announced the U.S. Food and Drug Administration has approved Herceptin Hylecta™ for subcutaneous injection for the treatment of certain people with HER2-positive early breast cancer in combination with chemotherapy and HER2-positive metastatic breast cancer in combination with paclitaxel or alone in people who have received one or more chemotherapy regimens for metastatic disease.

Johnson & Johnson will participate in the Barclays Global Healthcare Conference on Thursday, Mar. 14, at the Loews Miami Beach Hotel, Miami, FL. Tom Cavanaugh, President, Oncology and Catherine Owen, President, Immunology will represent the Company in a session scheduled at 10:15 a.m. (Eastern Time).

The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company’s incentive programs.

The findings represent the first reported multi-site validation of blood-based biomarker panels at 10-12 weeks gestation to stratify pregnant patients for the risk of preterm birth

The School of Science, Engineering and Technology at St. Mary’s University in San Antonio, Texas, is launching a new Bachelor of Science in Bioinformatics. Students can enroll in the program in Fall 2019.

Albireo Pharma, Inc. (NASDAQ: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced its support for Rare Disease Day, and reaffirmed its commitment to patients and families living with progressive familial intrahepatic cholestasis (PFIC) and other rare cholestatic liver diseases.